References
- Chung TYR, Pang KLK, Lee WYW, et al. Survey on obesity and weight management [Internet]. Public Opin. Program. Univ. Hong Kong. Public Opinion Programme, The University of Hong Kong; 2015 [cited 2017 Oct 19]. Available from: https://www.hkupop.hku.hk/english/report/obesitySurvey2015/index.html
- Blanck HM, Khan LK, Serdula MK. Use of nonprescription weight loss products: results from a multistate survey. JAMA. 2001;286:930–935.
- Machado EC, Silveira M. d, Silveira V. d. Prevalence of weight-loss strategies and use of substances for weight-loss among adults: a population study. Cad Saude Publica. 2012;28:1439–1449.
- Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012;36:13–25.
- U.S. Food and Drug Administration Drug Safety Communications. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market [Internet]. 2020 [cited 2020 Feb 15]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market
- Yen M, Ewald MB. Toxicity of weight loss agents. J Med Toxicol. 2012;8:145–152.
- Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017;10:223–234.
- Lee HCH, Law CY, Chen ML, et al. 2,4-Dinitrophenol: a threat to Chinese body-conscious groups. J Chin Med Assoc. 2014;77:443–445.
- Ching CK, Chen SPL, Lee HHC, et al. Adulteration of proprietary Chinese medicines and health products with undeclared drugs: experience of a tertiary toxicology laboratory in Hong Kong. Br J Clin Pharmacol. 2018;84:172–178.
- Poon WT, Ng SW, Lai CK, et al. Factitious thyrotoxicosis and herbal dietary supplement for weight reduction. Clin Toxicol. 2008;46:290–292.
- Lau NK, Chong YK, Tang MH, et al. Desoxy-D2PM: a novel psychoactive substance in convenience stores. Hong Kong Med J. 2016;22:515.
- Tang MHY, Chen SPL, Ng SW, et al. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J Clin Pharmacol. 2011;71:250–253.
- Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36:205–213.
- Chen SPL, Tang MHY, Ng SW, et al. Psychosis associated with usage of herbal slimming products adulterated with sibutramine: a case series. Clin Toxicol. 2010;48:832–838.
- Tang MH, Hung LY, Lai CK, et al. 9-year review of new psychoactive substance use in Hong Kong: a clinical laboratory perspective. Hong Kong J Emerg Med. 2019;26:179–185.
- The National Institute of Diabetes and Digestive and Kidney Diseases. Prescription medications to treat overweight and obesity [Internet]. [cited 2020 Feb 15]. Available from: https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
- Yuen YP, Lai CK, Poon WT, et al. Adulteration of over-the-counter slimming products with pharmaceutical analogue–an emerging threat. Hong Kong Med J. 2007;13:216–220.
- James WPT, Caterson ID, Coutinho W, et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–917.
- Cohen PA, Benner C, McCormick D. Use of a pharmaceutically adulterated dietary supplement, Pai You Guo, among Brazilian-born women in the United States. J Gen Intern Med. 2012;27:51–56.
- Chong CSY. Psychosis related to the use of sibutramine disguised as over-the-counter herbal weight loss remedies: a report of two patients. East Asian Arch Psychiatry. 2010;20:186–189.
- Lam PK, Leung KS, Wong TW, et al. Serotonin syndrome following overdose of a non-prescription slimming product containing sibutramine: a case report. Hum Exp Toxicol. 2012;31:414–417.
- Lam SK, Wong OF, Fung HT, et al. Sibutramine associated cardiac arrest in a Chinese healthy young lady. Hong Kong J Emerg Med. 2013;20:45–49.
- Chan TYK. Potential risks associated with the use of herbal anti-obesity products. Drug Saf. 2009;32:453–456.
- Mariotti S, Martino E, Cupini C, et al. Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. N Engl J Med. 1982;307:410–412.
- Dolfing JG, Wolffenbuttel BHR, ten Hoor-Aukema NM, et al. Daily high doses of fluoxetine for weight loss and improvement in lifestyle before bariatric surgery. Obes Surg. 2005;15:1185–1191.
- Cohen PA, Goday A, Swann JP. The return of rainbow diet pills. Am J Public Health. 2012;102:1676–1686.